Mechanism(s) of Selective Systolic Blood Pressure Reduction after a Low-Dose Combination of Perindopril/Indapamide in Hypertensive Subjects: Comparison with Atenolol

Journal of the American College of Cardiology

Volumn 43, Issue 1, 2004, Pages 92-99

  London, Gérard M ^a   Asmar, Roland G ^b   O'Rourke, Michaël F ^c   Safar, Michel E ^d  

^a Hopital Manhes   (France)

^b L'Institut CardioVasculaire   (France)

^c ST VINCENT S HOSPITAL   (Australia)

^d HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INDAPAMIDE; PERINDOPRIL;

ADULT; AGED; ARTICLE; CAROTID ARTERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; FOLLOW UP; HEMODYNAMIC MONITORING; HUMAN; HYPERTENSION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; THORACIC AORTA;

EID: 0347683347     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2003.07.039     Document Type: Article

References (21)

1. Yusuf S, Sleight P, Pogue J, Davies R, Dagenais G. Effects of angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcome Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53.
2. Lewis EJ, Hunsicker LG, Clarke WR, et al., and Collaborative Study Group. Renoprospective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.
3. Brenner BM, Cooper ME, De Zeeuw D, et al., and RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.
4. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention End point reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002;359:995-1003.
5. O'Rourke MF, Nichols WW. Effect of ramipril on cardiovascular events in high-risk patients. N Engl J Med 2000;343:64-6.
6. Sagie A, Larson MG, Levy D. The natural history of borderline isolated systolic hypertension. N Engl J Med 1993;329:1912-7.
7. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997;157:2413-46.
8. PROGRESS Collaborative Group. Randomized trial of a perindopril-based blood pressure-lowering regimen among 6,105 individuals with previous stroke of transient ischemic attack. Lancet 2001;358:1033-41.
9. Asmar RG, London GM, O'Rourke ME, Safar ME, and for the REASON Project Coordinators and Investigators. Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril/indapamide combination in hypertensive patients: a comparison with atenolol. Hypertension 2001;38:922-6.
10. Nichols WW, O'Rourke M. McDonald's Blood Flow in Arteries. Theoretical, Experimental and Clinical Principles, 4th edition. London, Sydney, Auckland: Arnold E, 1998:54-401.
11. Nichols WW, Singh BM. Augmentation index as a measure of peripheral vascular disease state. Curr Opin Cardiol 2002;17:543-51.
12. Pannier BM, Guerin AP, Marchais SJ, London GM. Different aortic reflection wave responses following long-term angiotensin-converting enzyme inhibition and beta-blocker in essential hypertension. Clin Exp Pharmacol Physiol 2001;28:1074-7.
13. Nichols WW, Edwards DG. Arterial elastance and wave reflection augmentation of systolic blood pressure: deleterious effects and implications for therapy. J Cardiovasc Pharmacol Ther 2001;6:5-21.
14. Chen CH, Ting CT, Lin SJ, et al. Different effects of fosinopril and atenolol on wave reflections in hypertensive. Hypertension 1995;25:1034-41.
15. O'Rourke MF. Effects on ACE inhibitor therapy on derived central arterial waveforms in hypertension (letter). Am J Hypertens 2002;15:476.
16. Safar M, Van Bortel L, Struijker-Boudier H. Resistance and conduit arteries following converting enzyme inhibition in hypertension. J Vasc Res 1997;81:34-67.
17. Intengan HD, Thibault G, Li JS, Schiffrin EL. Resistance artery mechanics, structure, and extracellular components in spontaneously hypertensive rats: effects of angiotensin receptor antagonism and converting enzyme inhibition. Circulation 1999;100:2267-75.
18. Girerd X, Giannattasio C, Moulin C, Safar M, Mancia G, Laurent S. Regression of radial artery wall hypertrophy and improvement of carotid artery compliance after long term antihypertensive treatment in elderly patients. J Am Coll Cardiol 1998;31:1064-73.
19. Ting CT, Chen C-H, Chang M-S, Yin FCP. Short- and long-term effects of antihypertensive drugs on arterial reflections compliance and impedance. Hypertension 1995;26:524-30.
20. Guerin AP, Blacher J, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation 2001;103:987-92.
21. Safar ME, Blacher J, Pannier B, et al. Central pulse pressure and mortality in end-stage renal disease. Hypertension 2002;39:735-8.